These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12199339)
1. When should we measure growth hormone binding protein? Baumann G J Pediatr Endocrinol Metab; 2002; 15(7):959-61. PubMed ID: 12199339 [No Abstract] [Full Text] [Related]
2. Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS). Ranke MB; Wollmann HA; Savage MO J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():259-66. PubMed ID: 10698590 [No Abstract] [Full Text] [Related]
3. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). Laron Z J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():231-49. PubMed ID: 10698588 [TBL] [Abstract][Full Text] [Related]
4. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. Attie KM; Julius JR; Stoppani C; Rundle AC J Pediatr; 1997 Jul; 131(1 Pt 2):S56-60. PubMed ID: 9255230 [TBL] [Abstract][Full Text] [Related]
5. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. Woods KA; Fraser NC; Postel-Vinay MC; Savage MO; Clark AJ J Clin Endocrinol Metab; 1996 May; 81(5):1686-90. PubMed ID: 8626815 [TBL] [Abstract][Full Text] [Related]
6. Growth hormone insensitivity associated with a STAT5b mutation. Kofoed EM; Hwa V; Little B; Woods KA; Buckway CK; Tsubaki J; Pratt KL; Bezrodnik L; Jasper H; Tepper A; Heinrich JJ; Rosenfeld RG N Engl J Med; 2003 Sep; 349(12):1139-47. PubMed ID: 13679528 [No Abstract] [Full Text] [Related]
7. Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. Rosenbloom AL J Pediatr; 1999 Sep; 135(3):280-9. PubMed ID: 10484790 [No Abstract] [Full Text] [Related]
8. Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. Goddard AD; Dowd P; Chernausek S; Geffner M; Gertner J; Hintz R; Hopwood N; Kaplan S; Plotnick L; Rogol A; Rosenfield R; Saenger P; Mauras N; Hershkopf R; Angulo M; Attie K J Pediatr; 1997 Jul; 131(1 Pt 2):S51-5. PubMed ID: 9255229 [TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. Vidarsdottir S; Walenkamp MJ; Pereira AM; Karperien M; van Doorn J; van Duyvenvoorde HA; White S; Breuning MH; Roelfsema F; Kruithof MF; van Dissel J; Janssen R; Wit JM; Romijn JA J Clin Endocrinol Metab; 2006 Sep; 91(9):3482-5. PubMed ID: 16787985 [TBL] [Abstract][Full Text] [Related]
18. Atypical GH insensitivity syndrome and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the GH receptor, including a novel frameshift mutation affecting the intracellular domain. Aisenberg J; Auyeung V; Pedro HF; Sugalski R; Chartoff A; Rothenberg R; Derr MA; Hwa V; Rosenfeld RG Horm Res Paediatr; 2010; 74(6):406-11. PubMed ID: 20606392 [TBL] [Abstract][Full Text] [Related]
19. Girls with Laron syndrome having positive growth hormone binding protein (GHBP) are less retarded in height than those lacking GHBP. Laron Z; Desai M; Silbergeld A J Pediatr Endocrinol Metab; 1997; 10(3):305-7. PubMed ID: 9388824 [No Abstract] [Full Text] [Related]